Oddo Bhf Analysts Give Merck KGaA (MRK) a €125.00 Price Target

Oddo Bhf set a €125.00 ($145.35) target price on Merck KGaA (FRA:MRK) in a research note issued to investors on Friday, October 27th. The brokerage currently has a buy rating on the healthcare company’s stock.

MRK has been the topic of several other reports. HSBC Holdings plc set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the company a neutral rating in a report on Wednesday, August 9th. Independent Research GmbH set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Wednesday, September 6th. Kepler Capital Markets set a €115.00 ($133.72) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, October 4th. J P Morgan Chase & Co set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, October 6th. Finally, Berenberg Bank set a €116.00 ($134.88) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Tuesday, September 19th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €108.61 ($126.29).

Shares of Merck KGaA (MRK) opened at €90.46 ($105.19) on Friday. Merck KGaA has a 1-year low of €89.21 ($103.73) and a 1-year high of €115.00 ($133.72).

TRADEMARK VIOLATION WARNING: “Oddo Bhf Analysts Give Merck KGaA (MRK) a €125.00 Price Target” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/11/13/merck-kgaa-mrk-given-a-125-00-price-target-by-oddo-bhf-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply